Leiden Gonzalez Pimentel, MD
General Practice · Lakeland, FLNPI 1801198791
Payments from drug & device makers
Across 327 payments — averaging $29.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- Lilly USA, LLC$900
- AbbVie$686
- Novo Nordisk$670
- Sanofi-aventis U.S. LLC$661
- Merck$408
- plus $3K from 25 others
What the payments were for
- Food & beverage$9,564100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 82 | $3,178 |
| Lilly USA, LLC | 39 | $900 |
| AbbVie | 26 | $686 |
| Novo Nordisk | 27 | $670 |
| Sanofi-aventis U.S. LLC | 33 | $661 |
| Merck | 7 | $408 |
| Boehringer Ingelheim | 15 | $332 |
| GSK | 18 | $327 |
| Amgen | 9 | $323 |
| Pfizer | 14 | $319 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $228 |
| Dexcom, Inc. | 6 | $222 |
| Johnson & Johnson | 5 | $203 |
| Esperion Therapeutics, Inc. | 3 | $146 |
| Novartis | 8 | $144 |
| Amarin Pharma, Inc. | 3 | $138 |
| Abbott | 7 | $125 |
| Idorsia Pharmaceuticals US Inc | 3 | $109 |
| Bayer | 4 | $93 |
| Exact Sciences | 2 | $63 |
| Boston Scientific | 1 | $52 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $45 |
| Teva Pharmaceuticals USA, Inc. | 2 | $30 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $24 |
| Genentech USA, Inc. | 1 | $23 |
| Shield Therapeutics Inc | 1 | $22 |
| Inspire Medical Systems, Inc. | 1 | $21 |
| E.r. Squibb & Sons, L.L.C. | 1 | $20 |
| Biohaven Pharmaceuticals, Inc. | 1 | $18 |
| Xeris Pharmaceuticals, Inc. | 1 | $17 |
| Lucid Diagnostics Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,564 in reported general payments places this provider in the 95th percentile of 6,901 general practice providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 122 | $132,696 |
| OzempicSemaglutide | 111 | $124,565 |
| EliquisApixaban | 73 | $90,584 |
| JardianceEmpagliflozin | 79 | $89,862 |
| FarxigaDapagliflozin Propanediol | 84 | $86,852 |
| TrulicityDulaglutide | 54 | $63,836 |
| EntrestoSacubitril/Valsartan | 25 | $29,780 |
| JanuviaSitagliptin Phosphate | 28 | $22,805 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 32 | $22,788 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 32 | $21,065 |
| Tresiba Flextouch U-200Insulin Degludec | 11 | $19,447 |
| Tresiba Flextouch U-100Insulin Degludec | 38 | $15,856 |
| RybelsusSemaglutide | 14 | $13,850 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 77 | $9,812 |
| LinzessLinaclotide | 12 | $9,672 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humulin 70-30 | $900 | $202,041199 claims |
| Novo NordiskOzempic, Rybelsus | $670 | $138,415125 claims |
| PfizerEliquis | $319 | $90,58473 claims |
| AstraZenecaFarxiga, Symbicort | $3,178 | $90,05897 claims |
| Boehringer IngelheimJardiance | $332 | $89,86279 claims |
| NovartisEntresto | $144 | $29,78025 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $661 | $26,96066 claims |
| MerckJanuvia | $408 | $22,80528 claims |
| GSKTrelegy Ellipta | $327 | $22,78832 claims |
| AbbVieLinzess, Synthroid | $686 | $13,32650 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,901 general practice providers in Florida.
Other general practice in Lakeland
- Jose CardonaMiami$71M
- Lawrence GalitzMiami Gardens$42.5M
- Armando AcevedoMiami$15.2M
- Jorge AmayaMiami$14.2M
- Frank AlvarezHialeah$13.6M
- Hector RodriguezMiami$12.8M
- Eddie ArmasSouth Miami$12.4M
- Idalia AcostaMiami$11.4M
- Lilia Rodriguez AblesMiami$10.7M
- Jorge Monroy AvellaOcoee$10.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.